Aytu BioPharma (NASDAQ:AYTU) reported quarterly earnings results on February 03, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-1.05, missing the consensus estimate of $-0.40 by $0.65 per share. Revenue came in at $15.2M, beating the estimate of $12.1M.
Aytu BioPharma's stock moved following the earnings release. The stock currently trades at $2.35 with a market capitalization of $16.5M.
